Ascendis Health Limited (Incorporated in the Republic of South Africa) (Registration number: 2008/005856/06) Share code: ASC ISIN: ZAE000185005 ("Ascendis" or "the Company")



TRADING STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2023

In terms of the Listings Requirements of the JSE Limited, a listed company is required to publish a trading statement as soon as a reasonable degree of certainty exists that the financial results for the period to be reported on next will differ by 20% or more from the financial results for the previous published corresponding period.

Accordingly, the board of directors of Ascendis advises shareholders that it is reasonably certain that the financial results for the six-month period ended 31 December 2023, when compared with the published results for the six-month period ended 31 December 2022 ("**prior corresponding period**"), are expected to be as follows:

Continuing Operations:

- earnings per share from continuing operations will be between 9.2 cents and 11.2 cents, compared to the loss per share from continuing operations of 29.4 cents reported for the prior corresponding period;
- headline earnings per share from continuing operations will be between 9.2 cents and 11.2 cents, compared to the headline loss per share from continuing operations of 29.4 cents reported for the prior corresponding period; and

Total Operations:

- earnings per share will be between 11.4 cents and 14.0 cents, representing a decrease of between 64.8% and 56.9% compared to the earnings per share from total operations of 32.5 cents reported for the prior corresponding period; and
- headline earnings per share will be between 11.4 cents and 14.0 cents, compared to the headline loss per share from total operations of 27.4 cents reported for the prior corresponding period.

This trading statement is the responsibility of the directors and the financial information on which this statement is based has not been reviewed or reported on by the external auditors of the Company.

The expected publication date of the unaudited results for the six months ended 31 December 2023 is 28 March 2024.

Johannesburg 26 March 2024

Sponsor

Valeo Capital (Pty) Ltd